Elwyn C. Cabebe

863 total citations
13 papers, 334 citations indexed

About

Elwyn C. Cabebe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Elwyn C. Cabebe has authored 13 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Elwyn C. Cabebe's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Elwyn C. Cabebe is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Elwyn C. Cabebe collaborates with scholars based in United States, New Zealand and Ireland. Elwyn C. Cabebe's co-authors include Heather A. Wakelee, George A. Fisher, Jacqueline V. Aredo, Jonathan W. Riess, Caroline E. McCoach, Ravi Salgia, Jarushka Naidoo, Billy W. Loo, Jessica A. Hellyer and Maximilian Diehn and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Thoracic Oncology.

In The Last Decade

Elwyn C. Cabebe

13 papers receiving 322 citations

Peers

Countries citing papers authored by Elwyn C. Cabebe

Since Specialization

Citations

This map shows the geographic impact of Elwyn C. Cabebe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elwyn C. Cabebe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elwyn C. Cabebe more than expected).

Fields of papers citing papers by Elwyn C. Cabebe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elwyn C. Cabebe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elwyn C. Cabebe. The network helps show where Elwyn C. Cabebe may publish in the future.

Co-authorship network of co-authors of Elwyn C. Cabebe

This figure shows the co-authorship network connecting the top 25 collaborators of Elwyn C. Cabebe. A scholar is included among the top collaborators of Elwyn C. Cabebe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elwyn C. Cabebe. Elwyn C. Cabebe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Automated patient selection and care coaches to increase advance care planning for patients with cancer 2024 ·JNCI Journal of the National Cancer Institute ·Michael F. Gensheimer, Winifred Teuteberg, Manali I. Patel, Divya Gupta, (unknown), (unknown), (unknown), (unknown), Ying Lü, (unknown), (unknown), (unknown), Jan C. DeNofrio, (unknown), Nigam H. Shah, Tai C. Chen, Elwyn C. Cabebe, Douglas W. Blayney, A. Dimitrios Colevas, Kavitha Ramchandran	3
2	MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy 2021 ·Journal of Thoracic Oncology ·Jacqueline V. Aredo, Jessica A. Hellyer, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Billy W. Loo, Maximilian Diehn, Heather A. Wakelee	1
3	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy 2021 ·Journal of Thoracic Oncology ·Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, (unknown), Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Heather A. Wakelee	86
4	Utility of incorporating a gene-based lung cancer risk test on uptake and adherence in a community-based lung cancer screening pilot study 2021 ·Preventive Medicine Reports ·Vincent K. Lam, (unknown), Paul R. Billings, Elwyn C. Cabebe, Robert P. Young	2
5	Community Low-Dose CT Lung Cancer Screening: A Prospective Cohort Study 2014 ·Lung ·Vincent K. Lam, Mary K. Miller, (unknown), (unknown), Robert P. Young, Elwyn C. Cabebe	15
6	A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer 2011 ·Investigational New Drugs ·Elwyn C. Cabebe, George A. Fisher, Branimir I. Šikić	9
7	Adjuvant Treatment of Resected Lung Cancer 2009 ·Proceedings of the American Thoracic Society ·(unknown), Elwyn C. Cabebe, Heather A. Wakelee	18
8	Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer 2008 ·Journal of Clinical Oncology ·Elwyn C. Cabebe, Tzu‐Ting Kuo, Albert C. Koong, Mark L. Welton, Andrew Shelton, (unknown), James M. Ford, Branimir I. Šikić, (unknown), Jane E. Rogers, George A. Fisher	10
9	An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer 2008 ·Journal of Clinical Oncology ·Tzu‐Lei Kuo, Elwyn C. Cabebe, Albert C. Koong, Jonathan Norton, (unknown), James M. Ford, (unknown), (unknown), Branimir I. Šikić, George A. Fisher	2
10	Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer 2007 ·Expert Opinion on Investigational Drugs ·Elwyn C. Cabebe, George A. Fisher	17
11	Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors 2007 ·Current Treatment Options in Oncology ·Elwyn C. Cabebe, Heather A. Wakelee	107
12	Sunitinib: A newly approved small-molecule inhibitor ofangiogenesis 2006 ·Drugs of today ·Elwyn C. Cabebe, Heather A. Wakelee	48
13	Intensity-modulated radiation therapy for the spine at the University of California, Irvine 2002 ·Medical dosimetry ·(unknown), Elwyn C. Cabebe, Muthana Al‐Ghazi, (unknown), Nilam Ramsinghani, Robert A. Sanford	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact